Immunodiagnostic Systems Share Discussion Threads

[silverfern] 28/11/2011 09:17

if growth is stalling then the price was high. THey are not saying nil growth but in the current climate today's caution has been enough and the price ash now halved n six months. I no longer hold but I wonder if the Count still has his 50k from the days these fell to 100p in 2008

[spacecake] 28/11/2011 07:54

Three days ago...

LONDON (Dow Jones)--U.K. diagnostics firm Omega Diagnostics Group PLC (ODX.LN) is planning to establish a direct sales presence in the U.S. market to capitalize on the launch next year of a range of automated diagnostic tests, the company's sales director said Friday.

Omega currently has its own sales forces in the U.K., Germany, and India, and sells through distributors to all major markets around the world. The establishment of a direct U.S. presence "features in [the company's] plans" over the next year, Sales Director Jag Grewal told Dow Jones Newswires.

In March the company signed an exclusive worldwide deal to develop allergy tests for Immunodiagnostic Systems Holdings PLC's (IDH.LN) flagship IDS-iSYS analyzer instrument. Omega plans to launch tests for between 50 and 100 common allergies during 2012, Chief Executive Andrew Shepherd told Dow Jones Newswires.

The iSYS machine can process 250 tests a day, compared with around 20 or 30 in a week for Omega's existing manual tests, so will open up a new market of larger clinical laboratories to the company, according to Shepherd.

The company has previously said the launch of iSYS tests will help it accelerate revenue growth. Comparable revenue was up 6.5% in the six months ended Sept. 30.

--------------------------------------------------------------------------------------------------------------------------------------
Today, not much of a profit warning due to the increase in competition.....

Outlook

As we announced at the time of our full year results in June, we expect the demand for vitamin D testing will continue to grow, albeit at lower rates than experienced in recent years. This appears to be the case with growth continuing in both manual and automated testing.

The impending introduction of competing automated products from some major manufacturers has coincided with efforts to contain health budgets, particularly in the USA. As a result we are beginning to see increasing price pressure, particularly on our larger accounts, and some disruption to equipment ordering patterns which we believe will persist in the short term and it is likely that this will impact negatively on our placement rate for the current period. As we noted earlier there are a number of global account discussions that are underway although the likely outcome and duration of these discussions remains uncertain.

[philo124] 28/11/2011 07:26

Gone ex growth, costs out of control. Revenue up nearly 5m only 10% of which fell to bottom line.

[pentangle] 24/11/2011 10:10

Not currently a holder, but I would not necessarily say that a warning is coming. IDH share price action mirrors many other small caps currently, where bad news has neither appeared nor seems imminent. May well be market led not IDH led.

[alftupper] 23/11/2011 15:50

The rapid descent in the share price is indicative of a forthcoming warning - things do not happen like this for no reason.

[wjccghcc] 21/10/2011 13:38

I think it's more because one of their competitors said the Vitamin D testing market was reaching saturation.

[philo124] 21/10/2011 08:17

Spot on pentangle, i did the same fwiw, but would buy in again on a very bad
day if it arises.

[pentangle] 20/10/2011 10:59

I think it is indicative of the state of the stock market at present rather than anything sinister happening to the company AFAIK. People have made a lot of money on IDH and are tending to grab profits whilst they are still there.

I had a lot of these, but sold out north of £11 (should have hung on for nearly a pound more), not because I had lost faith in the company, but because at a prospective PER of nearly 20 they did not look very cheap to me.

May be tempted to buy back in if they go much lower!! At a prospective PER of under 15 they are not bad value.

[alftupper] 20/10/2011 10:38

something has gone wrong here - it has lost 25% plus of its value in just over a month

[spacecake] 14/10/2011 11:23

Gapped down today, strange after the good trading update. Is the high PE ratio holding this back ?, might we see 850p again?

[energeticbacker] 07/10/2011 13:03

Hate the rental model but you can't knock the numbers - new comment in Small Cap Review www.investorschampion.com

[alter ego] 06/10/2011 12:13

Yes, but much better than a poor update which would see the stock trashed.

[philo124] 06/10/2011 11:49

Yes.In this market price imo is up with events, which i know is a bit harsh.

[alter ego] 06/10/2011 10:55

good trading update

[silverfern] 15/8/2011 19:23

what a buying opportunity, so I bought

[spacecake] 04/8/2011 14:17

Wow, down about 20% in a few days !

[philo124] 28/7/2011 07:38

So it did get to £12. I sold.

[philo124] 01/7/2011 18:22

Or Not. V Good close.

[philo124] 01/7/2011 14:32

Allergies might be a good idea.

[spacecake] 01/7/2011 14:13

MEDICAL test firm Immunodiagnostic Systems Holdings is on the look-out for suitable acquisitions as it bids to boost the number of tests available on its inautomated system.

IDS launched the IDS-iSYS machine to offer effective and speedy testing for clinical and research customers, and has expanded its range of tests from one to nine.

However, the Boldon-based firm aims to boost the number of assays it can provide in the next few years, and is interested in making company acquisitions to expand its portfolio of tests.

The company hopes to add another 12 assays in the next two years.

CEO Ian Cookson said: "I can't say where they will be, but that's our strategy going forward."

IDS currently provides testing kits for hypertension, bone testing and growth disorders, and is one of the major testers for Vitamin D in the world. It also has tests for diabetes on the horizon, but these will not emerge for several years.

It expects sales of £58.6m in 2012, increasing to £68.3m in 2013 and £75.8m in 2014, and plans to increase its North East workforce by around 50 in this time.

[jon l] 30/6/2011 11:39

Breaking free at last. This completes a rather neat inverse head and shoulders continuation pattern below £10 going back to October. Upward trend renewed and at least £2 in the current move if the tealeaves mean anything.

[philo124] 29/6/2011 00:07

56.6p, 2012. in fairness they see eps growth slowing in 2013/2014; 67p and 75p
respectively.

[valustar1] 28/6/2011 20:47

What are the Brewin eps forecasts for this year?

[dasv] 28/6/2011 20:43

Phil - can you paste the note here if poss? Glad I bought back in after Japan.